At a Glance
- Company: Cellares and Papillon Therapeutics.
- Location: South San Francisco and San Diego.
- Deal value: Not disclosed.
- Focus area: Friedreich’s ataxia and gene-corrected HSPC therapy.
- Next steps: Cellares will move PPL-001 manufacturing onto its Cell Shuttle and Cell Q platforms.
What happened?
Cellares and Papillon Therapeutics have announced a collaboration to automate manufacturing of PPL-001, Papillon’s investigational gene-corrected hematopoietic stem and progenitor cell therapy for Friedreich’s ataxia. The programme targets the GAA repeat expansion in the FXN gene, the mutation responsible for more than 95% of cases.
Why does it matter?
Friedreich’s ataxia is a rare, inherited, multi-system disease with no approved curative treatment. The partnership matters because it could make a complex cell therapy more reproducible, scalable and potentially more affordable to manufacture.
Who’s behind it?
Papillon Therapeutics is developing PPL-001 and positions the therapy as a potentially lifetime-durable treatment for a severe childhood-onset disease. Cellares is the manufacturing partner, providing its integrated cell therapy platforms to support both clinical development and future commercial production.
How was it achieved?
Cellares will transfer PPL-001’s process onto its Cell Shuttle end-to-end manufacturing platform and use Cell Q for automated quality control and release testing. The closed-system workflow is intended to reduce variability and improve process consistency for gene-corrected HSPC therapies.
What’s next?
The collaboration should support future clinical development and, later, commercial launch if the programme succeeds. PPL-001 already has Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA, with development supported in part by CIRM, FARA and the NIH.